142
Participants
Start Date
October 31, 2006
Primary Completion Date
April 30, 2009
Study Completion Date
April 30, 2011
phenoxodiol
400mg phenoxodiol three times daily in 28 day cycles.
carboplatin
AUC=2 weekly in 28 day cycles
placebo
every 8 hours daily in 28 day cycles
Royal North Shore Hospital, Sydney
UZ Antwerpen, Edegem
UZ Leuven, Leuven
New York Downtown Hospital, New York
Schwartz Gynecologic Oncology, Brightwaters
University of Rochester Gynecologic Oncology Associates, Rochester
IEO- Istituto Europeo di Oncologia, Milan
Greater Baltimore Medical Centre, Baltimore
Northern Virginia Pelvic Surgery Associates, Annadale
Wake Forest University Health Sciences, Winston-Salem
Brody School of Medical at East Carolina University, Greenville
Carolinas Medical Center, Charlotte
Piedmont Hospital, Atlanta
Medical College of Georgia Cancer Center, Augusta
Gynecologic Oncology Associates, Pembroke Pines
Sarah Cannon Research Institute, Nashville
Chattanooga GYN Oncology, Chattanooga
Chattanooga's Program In Women's Oncology, Chattanooga
Hall and Martin MDS, P.C., Knoxville
OSU James Cancer Hospital & Solove Research Institute, Columbus
MetroHealth Medical Center, Cleveland
Gabrail Cancer Center, Canton
Hospital General Universitario de Valencia, Valencia
Providence Hospital and Medical Centers, Southfield
Gynecologic Oncology of West Michigan, Grand Rapids
Associates in Women's Health, Wichita
Hematology and Oncology Specialists, LLC, Metairie
University of Texas Southwestern Medical Center Simmons Comprehensive Cancer Center, Dallas
Baylor College of Medicine, Houston
Hope Cancer Clinic, Brownsville
Arizona Clinical Research Center, Inc., Tuscon
Kaiser Permanente Los Angeles Medical Center, Los Angeles
Cedars-Sinai Medical Center, Los Angeles
Glendale Adventist, Glendale
Gynecology Oncology Associates, Newport Beach
Virginia Mason Medical Center Department of Hematology/Oncology, Seattle
Yale University School of Medicine, New Haven
Hematology Oncology, PC (Carl and Dorothy Bennett Cancer Center), Stamford
The Center for Cancer & Hematological Disease, Cherry Hill
Hospital del Mar, Barcelona
Jersey Shore Medical Center, Neptune City
The University of New Mexico Cancer Research and Treatment Center, Albuquerque
Miami Valley Hospital, Dayton
Prince of Wales Hospital, Randwick
Westmead Hospital, Westmead
Mater Adult Hospital, Brisbane
Royal Adelaide Hospital, Adelaide
Istitutio Fisioterapici Ospitaleri, Roma
Bialostockie Centrum Onkologii im. Marii Sklodowskiej-Curie Oddzial Onkologii Ginekologicznej, Bialystok
Ackademickie Centrum Kliniczne-Szpital, Akademii Medycznej w Gdansku, Gdansk
Centrum Onkologii-Instytut im. M. Sklodowskiej-Curie, Oddzial w Gliwicach, Gliwice
Centrum Onkologii - Instytut im. M. Sklodowskiej-Curie Oddzial w Krakowie Klinika Ginekologii Onkologicznej, Krakow
Centrum Onkologii Ziemi, Lublin
Ginekologiczno - Polozniczy Szpital Kliniczny AM im. K. Marcinkowskiego w Poznaniu SPZOZ Klinika Onkologii Ginekologicznej, Poznan
Centrum Onkologii-Instytut im. M. Sklodowskiej Curie Klinika Nowotworow Narzadow Plciowych Kobiecych, Warsaw
Hospital Germans Trias i Pujol, Badalona
Hospital General Universitario de Alicante, Alicante
Hospital General Vall d'Hebron, Barcelona
Hospital Clinic i Provincial de Barcelona, Barcelona
Yeovil District Hospital, Yeovil
Cancer Research UK Clinical Trials Unit Old Clinical Investigations Building, Birmingham
Ninewells Hospital, Dundee
Edinburgh Cancer Research Centre Western General Hospital, Edinburgh
The Beatson West of Scotland Cancer Centre, Glasgow
St James University Hospital, Leeds
Hammersmith Hospital, London
Cancer Research UK & UCL Cancer Trials Center, London
Clatterbridge Centre for Oncology, Metropolitan Borough of Wirral
Nottingham University Hospitals NHS Trust, Nottingham
Royal Marsden NHS Foundation Trust, Sutton
Lead Sponsor
MEI Pharma, Inc.
INDUSTRY